BUZZ - Charles River Corporation shares rise on raised 2026 performance forecast and long-term targets
路透社2026/09/24 15:01September 24 - ** Contract drug developer Charles River Laboratories (CRL.N) shares rose 6.1% to $294.16
** The company expects that its 2026 organic revenue growth rate and adjusted earnings per share will both reach the upper end of its earlier guidance ranges (0% to 1% and $11.15 to $11.45, respectively), citing continued strong demand from biotechnology and pharmaceutical clients
** The target is to achieve annual organic revenue growth of 5% to 7% and low double-digit adjusted earnings per share growth from 2027 to 2030
** Adjusted operating margin is expected to rise from the forecasted 21%–21.3% in 2026 to around 24% in 2030
** CRL plans to save over $300 million between 2027 and 2030 by streamlining operations and increasing the use of automation and digital tools
** Evercore ISI said the 5% to 7% revenue growth target exceeds expectations and is “highly achievable under normal market conditions,” but even with the $300 million cost-saving initiative, the margin target for 2030 could still be “somewhat surprising”
** Including today’s gains, CRL shares are up 47.7% so far this year
(To support non-native English speakers, Reuters offers automated translations of its reports in various languages. As there may be inaccuracies in automated translations or missing context, Reuters does not guarantee the accuracy of these texts, which are provided solely for readers' convenience. Reuters accepts no liability for any damages or losses arising from the use of the automated translation service.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.
After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.
Crypto prices
More
